SecBot SecBot
SECBOTREPLAY Home › Report › FOCL

FOCL · FocalTherics (formerly EDAP TMS) reported preliminary Q2 2026 HIFU…

EDAP TMS SA · 8-K filed Aug 11, 2026 at 17:04 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 11, 2026 at 17:04 ET

FocalTherics (formerly EDAP TMS) reported preliminary Q2 2026 HIFU revenue of $12.7M-$13.2M (+34-39% YoY), a record quarter, and announced the classification of its legacy ESWL and Distribution segments as discontinued operations, effectively becoming a pure-play robotic focal therapy company. The company also provided updates on its pipeline expansion into BPH and endometriosis, and highlighted a proposed +11.6% Medicare payment increase for HIFU in 2027. The strong preliminary results and strategic refocusing are positive, but the lack of full financials (EPS, operating cash flow) and the ongoing operating losses temper the bullishness.

  • Preliminary Q2 2026 HIFU revenue of $12.7M to $13.2M, representing 34% to 39% YoY growth.
  • Record 13 Focal One system sales in Q2 2026, up 44% YoY.
  • Global installed base of Focal One systems reached 184, up from 146 in Q2 2025.
  • U.S. Focal One procedure volume grew 47% YoY.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access